Compare Marqeta Inc (MQ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs BIO-TECHNE Corp — how do they compare? Marqeta Inc trades at $15.59 (market cap $1.62B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 6.9× Marqeta Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| MQ | TECH | |
|---|---|---|
Market Cap | $1.62B | $11.24B |
Sector | Technology | Health |
52-Week High | $26.00 | $72.29 |
52-Week Low | $15.04 | $43.31 |
Enterprise Value | $939.53M | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $15.96, down 4.37% on the day, with a bearish technical signal. The company reported Q2 2026 earnings with a beat on EPS and 17% net revenue growth, marking its second consecutive quarter of GAAP profitability. Recent partnerships with Google and Riskified highlight strategic expansion. However, valuation ratios remain elevated with a P/E of 177.28, and net income margin is thin at 1.53%.
The outlook is mixed; analyst consensus is a Buy with a $19.00 price target, implying upside, but execution on growth initiatives like stablecoin cards and European expansion is key. Risks include high valuation sensitivity and competitive pressures in fintech. Positive cash flow trends and recent profitability improvements provide a foundation for cautious optimism.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
